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ttp://dx.doi.org/10.1016/j.jmoldx.2016.07.006Next-generation sequencing (NGS) has rapidly replaced Sanger sequencing as the method of choice for
diagnostic gene-panel testing. For hereditary-cancer testing, the technical sensitivity and speciﬁcity of
the assay are paramount as clinicians use results to make important clinical management and treatment
decisions. There is signiﬁcant debate within the diagnostics community regarding the necessity of
conﬁrming NGS variant calls by Sanger sequencing, considering that numerous laboratories report
having 100% speciﬁcity from the NGS data alone. Here we report our results from 20,000 hereditary-
cancer NGS panels spanning 47 genes, in which all 7845 nonpolymorphic variants were Sanger-
sequenced. Of these, 98.7% were concordant between NGS and Sanger sequencing and 1.3% were
identiﬁed as NGS false-positives, located mainly in complex genomic regions (A/T-rich regions, G/C-rich
regions, homopolymer stretches, and pseudogene regions). Simulating a false-positive rate of zero by
adjusting the variant-calling quality-score thresholds decreased the sensitivity of the assay from 100%
to 97.8%, resulting in the missed detection of 176 Sanger-conﬁrmed variants, the majority in complex
genomic regions (n Z 114) and mosaic mutations (n Z 7). The data illustrate the importance of
setting quality thresholds for panel testing only after thousands of samples have been processed and
the necessity of Sanger conﬁrmation of NGS variants to maintain the highest possible sensitivity.
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Ambry Genetics.Rapid technical advances in target enrichment and
next-generation sequencing (NGS) technologies have revo-
lutionized clinical diagnostic testing. The ability to simul-
taneously analyze all genes involved in a disease phenotype
at a reduced cost has enabled NGS to surpass conventional
capillary Sanger sequencing as the method of choice in most
high-throughput diagnostics laboratories.1 Targeted NGS
panel tests have become frontline assays for a wide variety
of inherited disorders. In accordance with the accessibility
of NGS, a multitude of diagnostics laboratories have
recently launched a broad range of inherited cancer-
susceptibility gene panels that test a wide variety of char-
acterized genes associated with hereditary cancers.2e6 The
accuracy of these tests can vary based on a number of
variables including the target enrichment platform,
sequencing technology, bioinformatics pipeline used, and
variant classiﬁcation experience. The technical sensitivity
and speciﬁcity of a hereditary-cancer test are paramount asstigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orgphysicians use the results to make important clinical man-
agement decisions such as costly specialized surveillance
and preventive surgery.
There is signiﬁcant debate within the diagnostic gene-
sequencing space regarding the necessity of conﬁrming
NGS-determined variant calls using a secondary technology
such as Sanger sequencing to avoid the possibility of
reporting out a false-positive result. Many laboratories are
resistant to Sanger-sequencing conﬁrmation as it requires
additional primer design, validation, clinical workﬂow, and
licensed personnel for chromatogram analysis, which
increase both the cost and turnaround time of testing.olecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Mu et alGuidance on NGS laboratory standards from the College of
American Pathologists leaves it up to the laboratory
performing the assay to determine whether conﬁrmation
testing is appropriate.7 In contrast, the American College of
Medical Genetics and Genomics recommends secondary
conﬁrmation testing for all NGS-reported variants.8 To date,
the data concerning the need for secondary conﬁrmation of
NGS calls in germline testing are severely limited by the use
of small data sets. Strom et al9 analyzed 110 variants from
144 exome samples and concluded that single-nucleotide
variants (SNVs) meeting a quality (Q) score of 500
should not require Sanger conﬁrmation. Similarly, Baud-
huin et al10 recently concluded, after their study in 77
samples, that Sanger conﬁrmation of NGS SNVs with
coverage of 100 and a Q score of 20 was “unneces-
sarily redundant.”
Validation data published and marketed by several
commercial and academic laboratories offering hereditary-
cancer NGS panel testing illustrated an analytical speciﬁcity
of 100%, detecting zero false-positives.3e5 However, it is
likely that these assays sacriﬁce analytical sensitivity by
missing true variants in complex genomic regions where
false-positives occur. Most disease-causing variants are rare
variants with minor allele frequencies of <0.1%.11 There-
fore, the appropriate balance between speciﬁcity and
sensitivity cannot be accurately deﬁned until thousands of
samples are processed. Here we report our results from
20,000 samples, the largest study to date, to determine the
necessity of Sanger-sequencing conﬁrmation of NGS vari-
ants and to accurately deﬁne the appropriate sensitivity and
speciﬁcity for a high-volume gene-panel diagnostic assay.Materials and Methods
Samples
A consecutive series of 20,000 patient samples referred to
Ambry Genetics (Aliso Viejo, CA) for NGS-basedTable 1 Genes Included in Next-Generation Sequencing Multigene Ca
Cancer type No. of genes
Breast cancer 17
Colorectal cancer 17
Paragangliomas/Pheochromocytomas 12
Renal cancer 19
Pancreatic cancer 13
Ovarian cancer/uterine cancer 24
*CDK4 is included in the comprehensive CancerNext test.
924multigene hereditary-cancer testing were included in the
study (Solutions Institutional Review Board protocol num-
ber 1OCT14e93). Data from multiple hereditary cancere
test offerings [BreastNext, ColoNext, PGLNext, RenalNext,
PancNext, GYNplus, OvaNext, and CancerNext (all from
Ambry Genetics)] were included in this study (Table 1).
During initial test validation of these panels on over 200
characterized samples, the sensitivity and speciﬁcity of the
assay were 100% and 99.99%, respectively. At least 6
to 7 mg of genomic DNA was extracted from whole blood or
saliva using the QiaSymphony instrument (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
Isolated DNA was quantiﬁed using a NanoDrop UV spec-
trophotometer (Thermo Fisher Scientiﬁc, Waltham, MA)
and/or Qubit Fluorometer (Life Technologies, Carlsbad,
CA), with quality metrics of A260/280 from 1.8 to 2.0 and
A260/230 of 1.6.
NGS Library Preparation and Sequencing
A customized target-enrichment oligonucleotide library was
designed to capture 49 hereditary cancererelated genes
(Integrated DNA Technologies, Coralville, IA). Genomic
DNA was mechanically sheared to 300-bp fragments with
an LE220 focused ultrasonicator (Covaris, Woburn, MA)
and NGS library prepared on a Freedom EVO100 auto-
mated system (Tecan, Mannedorf, Switzerland) according to
the manufacturer’s recommendation (Kapa Biosystems,
Wilmington, MA). Reactions were puriﬁed using AMPure
XP beads (Beckman Coulter, Brea, CA) and quantiﬁed on a
2200 TapeStation Instrument (Agilent Technologies, Santa
Clara, CA). Adapter-ligated DNA were hybridized in solu-
tion to customized biotinylated DNA oligonucleotides
complementary to the target sequences of interest (Inte-
grated DNA Technologies). After hybridization, Streptavi-
din Dynabeads (Life Technologies) were used to capture the
regions of interest and were PCR-ampliﬁed on a Bio-Rad
T100 thermal cycler (Bio-Rad Laboratories, Hercules, CA)ncer Panels
Gene list*
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A,
MUTYH, NBN, NF1, PTEN, RAD50, RAD51C, RAD51D, TP53, PALB2
APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2,
MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC,
SDHD, TMEM127, VHL
MLH1, MSH2, MSH6, PMS2, PTEN, TP53, VHL, EPCAM, FLCN,
TSC2, TSC1, SDHB, MET, MITF, SDHC, SDHD, SDHA, FH, BAP1
APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2,
MSH6, PMS2, STK11, TP53, PALB2
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1,
MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PMS2, PTEN, RAD50,
RAD51C, RAD51D, STK11, TP53, PALB2, SMARCA4
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Necessity of Sanger Sequencing in NGSwith the following conditions: 98C for 45 seconds;
followed by a program of 98C for 15 seconds, 65C for
30 seconds, and 72C for 30 seconds for 12 cycles; and
ending with a 1-minute extension at 72C. Final libraries
were puriﬁed using AMPure XP beads (Beckman Coulter)
and quantiﬁed on the 2200 TapeStation (Agilent Technol-
ogies) for normalization and pooling. Sequencing was
conducted on HiSeq2500 or NextSeq500 using 150-bp
paired-end conditions as described in the manufacturer’s
standard workﬂow (Illumina, San Diego, CA).
Data Analysis
Variants in all coding domains plus at least ﬁve bases into
the 50 and 30 ends of all introns, 50 untranslated region
(UTR) and 30UTR were used for analysis. Variants in
PMS2 exons 11 to 15 were excluded from analysis due to
interference with >99% homologous pseudogene
PMS2CL. Although BMPR1A, CHEK2, and SDHA also
contain highly homologous pseudogenes (98% to 99%),
there are enough intronic mismatches to differentiate them
when using 150-bp paired-end sequencing. EPCAM and
GREM1 cancer susceptibility is limited to gross abnor-
malities and so was not included in the NGS data.12,13 For
MITF, only the status of the c.952G>A (p.E318K) was
analyzed during testing.14 Data excluded gross deletions
and duplications as these were identiﬁed through a
customized microarray for testing. Initial data processing
and base calling, including extraction of cluster intensities,
were done using Real Time Analysis version 1.17.21.3
(HiSeq Control Software version 2.0.10; Illumina). Output
ﬁles were processed and demultiplexed using Casava
version 1.8.2 (Illumina). Sequence reads were aligned to
the reference human genome (GRCh37) using NovoAlign
version 3.02.07 (Novocraft Technologies, Selangor,
Malaysia) and variant calls generated using Genome
Analysis Toolkit version 3.2.2 (Broad Institute, Cambridge,
MA). Duplicate reads were removed before variant calling.
Variant calling was determined by multiple factors,
including base quality, mapping quality, haplotype,
coverage, number of nearby mismatches, and heterozygous
ratio. A minimal base-calling Q score of 17 on each base
was required. The variant-calling Q score of each variant is
a measurement indicating the conﬁdence of the speciﬁc
variant called. A minimal coverage of 10 and a Q score
of 30 were required for candidate variants to be called. Any
region with a depth of coverage of <10 was ﬁlled in by
Sanger sequencing. Data were annotated with the custom-
ized Variant Analyzer tool version 3.1 (Ambry Genetics),
including nucleotide and amino acid conservation,
biochemical nature of amino acid substitutions, and pop-
ulation frequency in Exome Sequencing Project,15 1000
Genomes Project,16 and internal Ambry data. Each variant
was classiﬁed as a pathogenic mutation, variant likely
pathogenic, variant of unknown signiﬁcance, likely benign,
or benign, following the methods of classiﬁcationThe Journal of Molecular Diagnostics - jmd.amjpathol.orgconsistent with the guideline from the American College of
Medical Genetics and Genomics.17 For variant classiﬁca-
tion, “likely” referred to a >95% likelihood of a variant
being disease causing or benign, as proposed by the In-
ternational Agency for Research on Cancer.18 This classi-
ﬁcation algorithm incorporated multiple lines of evidence
including co-segregation, co-occurrence, population fre-
quency, phenotype and family history, variant location,
structural impact, in silico predictions, and functional
studies. According to the American College of Medical
Genetics and Genomics guideline,17 truncating mutations
that occur close to the COOH-terminus and in-frame de-
letions/insertions may retain protein function; thus their
interpretation requires extra caution and additional evi-
dence such as functional assays for proper classiﬁcation.
All variants with likely clinical relevance (pathogenic
variants, likely pathogenic variants, and variants of un-
known signiﬁcance) were conﬁrmed by Sanger sequencing
in the sense and antisense directions regardless of whether
they had been detected previously. If a variant was not
conﬁrmed, Sanger sequencing was repeated with a second
set of unique PCR primers to avoid allele dropout. Variants
that failed to be conﬁrmed by Sanger sequencing were
identiﬁed as false-positive variants and were cleared from
reporting. A negative report was signed out if a sample had
a mean base Q score of >30, a percentage of perfect index
of >85%, a percentage of bases over Q30 of >75%, and no
detected clinically relevant variants.
To simulate a scenario of zero false-positives, a high
Q-score cutoff could be set to exclude all low-conﬁdence
variants. Therefore, by adjusting this metric, one could
control the number of false-positives that could be tolerated
in variant calling. In the data set, 20 of 47 genes had false-
positives; the maximal Q-scores of false-positives are listed
in Supplemental Table S1. We gradually simulated 20
scenarios by using 20 different Q-score thresholds, which
were uniformly distributed between the initial Q-score
threshold of 30 and a maximal Q score of known false-
positives. For example, ATM had a maximal Q score of
695; thus 20 different Q-score thresholds, in increments of
33, between 30 and 695 were simulated to gradually achieve
a scenario of zero false-positives. All variants having a
Q-score above a speciﬁc threshold were chosen for each
analysis. Thus, the highest sensitivity occurred when the
minimal Q score was used as the threshold in which the
most false-positives were included. The highest speciﬁcity
occurred when the maximal Q score was used as a threshold
in which no false-positives were included. Due to variant-
calling difﬁculties based on speciﬁc genomic content, the
simulation was repeated for all 47 genes individually
(Supplemental Figure S1).
Sanger Sequencing
Universally tagged primers (Integrated DNA Technologies)
were designed using Vector VNTI Advance version 11.5.1925
Figure 1 Polymorphic minor allele frequency (MAF) concordance be-
tween the data sets from the Ambry 20,000-sample study and Exome
Sequencing Project (ESP)15 and the 1000 Genomes Project16 (1000G).
A and B: Comparison of minor allele frequency of polymorphic variants
between ESP (A) and 1000G (B) and the Ambry 20,000-sample study
population.
Table 2 The Variant Type Distribution of Nonpolymorphic Vari-
ants that Were Concordant between Next-Generation Sequencing
and Sanger Sequencing
Genetic
variant Variant type No. of variants % of variants
SNV Synonymous 48 0.6
Missense 5817 75.1
Splicing 140 1.8
Nonsense 302 3.9
Methionine change 14 0.2
50UTR/30UTR/intron 497 6.4
Indel In-frame 148 1.9
Frameshift 721 9.3
Splicing 10 0.1
50UTR/30UTR/intron 49 0.6
SNV, single-nucleotide variant; UTR, untranslated region.
Mu et al(Life Technologies) and compared with those from public
databases to avoid SNPs and nonspeciﬁc ampliﬁcation.
Genomic DNA was ampliﬁed using the HotStarTaq Master
Mix Kit (Qiagen) with the following conditions: 95C for
15 minutes; followed by a program of 94C for 30 seconds,
60C for 30 seconds, and 72C for 45 seconds for 35 cycles;
and ending with a 10-minute extension at 72C. Amplicons
were puriﬁed using HT ExoSAP-IT (Affymetrix, Santa926Clara, CA) and bidirectionally sequenced using Big Dye
Terminator version 3.1 on an ABI3730xl DNA analyzer
(Applied Biosystems, Foster City, CA). Chromatogram
analysis was conducted using Sequence Pilot version 4.2.1
(JSI Medical Systems, Boston, MA).
Results
Clinical NGS testing of 47 hereditary-cancer genes in
20,000 consecutive patients identiﬁed 1,130,361 benign
polymorphic variants, 1773 pathogenic mutations, 204
likely pathogenic variants, and 5868 variants of unknown
signiﬁcance. Overall, the variants detected had a mean
heterozygous ratio of 66% (range, 10% to 100%), mean
coverage of 441 (range, 12 to 1204), and a mean Q
score of 8719 (range, Q30 to Q31,853). SNVs with Phred-
scaled P value of >60 and small insertions and deletions
(indels) with Phred-scaled P value of >200 were determined
as strand bias variants in Genome Analysis Toolkit version
3.2.2. Of detected variants, 99.99% of SNVs and 100% of
indels did not have strand bias. Although benign poly-
morphisms are not Sanger-conﬁrmed and are ﬁltered out for
diagnostic-testing purposes, the frequency of common
variants is a good internal quality-control metric to track. To
do so, the internal population frequencies of the 692 unique
polymorphism variants of the total of 1,130,361 benign
polymorphisms identiﬁed were compared with the
frequencies observed in publicly available data sets from the
Exome Sequencing Project15 and the 1000 Genomes Proj-
ect.16 Using the Pearson correlation coefﬁcient and the
KolmogoroveSmirnov test, there was signiﬁcant concor-
dance between Ambry Genetics’ internal data and the data
from the Exome Sequencing Project15 (Pearson correlation
coefﬁcientZ 0.978, KolmogoroveSmirnov test PZ 2.2e-
16) and the 1000 Genomes Project16 (Pearson correlation
coefﬁcient Z 0.978, KolmogoroveSmirnov test
P Z 2.998e-15) (Figure 1).
Conﬁrmatory Sanger-sequencing analysis was performed
on all 7845 nonpolymorphic variants, including pathogenicjmd.amjpathol.org - The Journal of Molecular Diagnostics
Necessity of Sanger Sequencing in NGSvariants, likely pathogenic variants, and variants of
unknown signiﬁcance, which consisted of 6912 (3481
unique) SNVs and 933 (432 unique) indels. Of these,
98.7% (n Z 7746) were concordant between NGS and
Sanger sequencing, with 3876 of them being unique. The
variant types and distribution of concordant variants are
listed in Table 2. The Sanger-conﬁrmed true-positives had a
mean heterozygous ratio of 46% (range, 10% to 100%),
mean coverage of 415 (range, 11 to 1204), and a
mean Q score of 2247 (range, Q38 to Q22,458). The
remaining 1.3% of variants (94 SNVs, 5 indels) were
cleared by Sanger sequencing and identiﬁed as NGS false-
positives, with 46 of them unique variants (Figure 2A,
Table 3, and Supplemental Table S2). The false-positives
detected had a mean heterozygous ratio of 16% (range,
10% to 40%) and mean coverage of 223 (range, 10 to
689).The Journal of Molecular Diagnostics - jmd.amjpathol.orgFalse-positives were not evenly distributed across all
genes as would be expected if they were random PCR or
sequencing artifacts. For example, 27 genes being tested
(APC, BAP1, BMPR1A, CDK4, CDKN2A, FH, FLCN,
MAX, MEN1, MET, MITF, MLH1, MSH6, NBN, POLD1,
RAD51C, SDHAF2, SDHB, SDHC, SDHD, SMARCA4,
STK11, TMEM127, TP53, TSC1, TSC2, and VHL) had no
false-positives (Table 3 and Figure 2B). Complex genomic
regions including homopolymer stretches, pseudogene
homology, and G/C-rich (65% G/C bases) and A/T-rich
(65% A/T bases) regions can impact false-positive
rates.19e21 Of the 99 false-positives detected in the
study, 46.7% were located in A/T-rich regions; 20.0%, in
G/C-rich regions; 14.1%, in homopolymer stretches; and
2.0%, in pseudogene regions, and 17.2% had no discern-
able genomic cause (Supplemental Table S2). Importantly,
26% (n Z 26) of false-positives identiﬁed representFigure 2 Characterization of next-generation sequencing (NGS)
false-positive variants. A: The false-positive proﬁle was determined by
plotting the NGS coverage against the variant read ratios. Variants were
either Sanger-conﬁrmed or Sanger-cleared. B: Gene-speciﬁc false-pos-
itive rates. Those genes with zero false-positives are excluded. Het,
heterozygous.
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Table 3 Gene-Speciﬁc Next-Generation Sequencing FPRs and
Simulated Sensitivity Analysis when FPR Adjusted to Zero
Gene
No. of Sanger-sequenced
variants* FPR
Sensitivity
when FPR Z 0%y
APC 309 0.00 100.00
ATM 857 1.63 94.90
BAP1 28 0.00 100.00
BARD1 235 0.85 97.00
BMPR1A 43 0.00 100.00
BRCA1 341 0.88 93.49
BRCA2 548 1.46 100.00
BRIP1 332 3.01 100.00
CDH1 131 3.05 96.06
CDK4 29 0.00 100.00
CDKN2A 40 0.00 100.00
CHEK2 653 0.15 97.70
FH 29 0.00 100.00
FLCN 33 0.00 100.00
MAX 4 0.00 100.00
MEN1 10 0.00 100.00
MET 38 0.00 100.00
MITF 5 0.00 100.00
MLH1 145 0.00 100.00
MRE11A 174 5.17 100.00
MSH2 309 1.94 83.50
MSH6 327 0.00 100.00
MUTYH 540 0.74 98.32
NBN 249 0.00 100.00
NF1 286 4.90 99.63
PALB2 302 0.66 100.00
PMS2 147 0.68 99.32
POLD1 91 0.00 100.00
POLE 133 2.26 94.62
PTEN 239 2.51 95.71
RAD50 359 1.39 99.44
RAD51C 181 0.00 100.00
RAD51D 135 2.96 96.18
RET 41 2.44 100.00
SDHA 34 2.94 100.00
SDHAF2 2 0.00 100.00
SDHB 29 0.00 100.00
SDHC 4 0.00 100.00
SDHD 15 0.00 100.00
SMAD4 41 2.44 100.00
SMARCA4 151 0.00 100.00
STK11 64 0.00 100.00
TMEM127 7 0.00 100.00
TP53 94 0.00 100.00
TSC1 25 0.00 100.00
TSC2 48 0.00 100.00
VHL 8 0.00 100.00
*All of the nonpolymorphic variants were conﬁrmed/cleared by Sanger
sequencing.
ySensitivity when pipeline false-positive rate is adjusted to zero.
FPR, false-positive rate.
Mu et alvariants present in the Ambry Genetics internal database
that had been previously Sanger-conﬁrmed and reported
out, illustrating that the ﬁltering of recurrent false-positives
as artifacts is not feasible (Supplemental Table S2). For928example, the founder pathogenic MUTYH mutation c.1187
G>A, which is located in a G/C-rich region and respon-
sible for MUTYH-associated polyposis, was identiﬁed as a
false-positive in three samples and Sanger-conﬁrmed 211
times in our data set. It is also evident that setting het-
erozygous read ratio and coverage ﬁlters for variant calling
that would completely eliminate the need for Sanger-
conﬁrming of variants would sacriﬁce sensitivity, as
conﬁrmed variants and false-positives are intermixed at
low coverage and heterozygous ratios (Figure 2A).
Without affecting sensitivity and speciﬁcity, setting a
conservative threshold of a >40% heterozygous read ratio
and >100 coverage for variants that do not need sec-
ondary conﬁrmation would decrease the Sanger-
sequencing burden by 87%.
To verify the importance of having a highly sensitive
assay for diagnostic testing, one that can detect true variants
at low coverage and low heterozygous ratios in which
false-positives generally reside, we gradually adjusted the
variant-calling threshold to achieve 100% speciﬁcity, elim-
inating all false-positives from the data. The sensitivity
[True-positives/(True-positives þ False-negatives)] and
false-positive rate [False-positives/(True calls þ False-
positives)] of the test were calculated at each incremental
adjustment. As the false-positive rate decreased from 1.3%
to 0%, the sensitivity of the assay decreased from 100% to
97.8%, resulting in the missed detection of 176 Sanger-
conﬁrmed variants (142 unique variants) (Table 3,
Supplemental Table S3, and Figure 3). The false-negatives
were concentrated in 13 genes (ATM, BARD1, BRCA1,
CDH1, CHEK2, MSH2, MUTYH, NF1, PMS2, POLE,
PTEN, RAD50, RAD51C, and RAD51D), ranging from
0.37% for NF1 to 16.50% of conﬁrmed calls missed for
MSH2 (Table 3, Figure 3, and Supplemental Figure S1). For
example, in the 20,000-sample cohort, the pathogenic
MSH2 splicing mutation c.942þ3A>T, located in the 30 end
of exon 5 in a difﬁcult-to-sequence homopolymer stretch of
27 adenines, was missed in 83% of patients harboring the
mutation (ﬁve of six) when the false-positive rate was
adjusted to zero (Figure 4). Likewise, CHEK2, which has
several highly homologous pseudogenes located on chro-
mosomes 2, 7, 10, 13, 15, 16, X, and Y, had a false-negative
rate of 2.7% in the simulated study.22 Similar to false-
positives, many of the false-negatives identiﬁed in the
study were located in complex genomic regions, with 45.5%
located in A/T-rich regions, 8.5%, in G/C-rich regions;
2.8%, in homopolymer stretches; 8%, in pseudogene re-
gions; and 35.2% had no discernable genomic region cause.
In addition, there were seven mosaic mutations missed in
ATM (n Z 4), BRCA1 (n Z 1), CHEK2 (n Z 1), and
RAD51D (n Z 1) (Supplemental Table S3). Variants were
identiﬁed as mosaic based on NGS low heterozygous read
ratios and Sanger-conﬁrmation chromatogram analysis
(Supplemental Figure S2).
The mean false-negative heterozygous ratio was 40%
(range, 10% to 69%) and mean coverage, 123 (range,jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 3 Simulated analysis illustrating the
loss of assay sensitivity when the false-positive
rate is adjusted to zero. A: Sensitivity versus
false-positive rate. As the false-positive rate is
reduced from a baseline value of 1.26% to 0%, the
sensitivity of the assay is reduced from 100% to
97.8%. B: The coverage and heterozygous read
ratio proﬁle of false-negatives when the false-
positive rate is reduced to zero. C: Gene-speciﬁc
false-negative rates when the false-positive rate
is reduced to zero. Those genes in which no false-
negatives occur in the simulated study are
excluded. Het, heterozygous.
Necessity of Sanger Sequencing in NGS11 to 625) (Figure 3). Importantly, approximately 18%
(n Z 32) of false-negatives had heterozygous read ratios
below 30% and 56% (n Z 98) and coverage under 100,
metrics similar to those attributed to false-positives (Figure 3).
Therefore, true variants can often have low coverage and low
heterozygous ratios, and therefore are indistinguishable, at
many loci, from false-positives. Having a bioinformatics
pipeline with 100% speciﬁcity will also ﬁlter out true variants
with balanced heterozygous ratios and good coverage. In the
study, 30.7% (nZ 54) of false-negatives had a heterozygous
ratio of40% and coverage of100 (Figure 3). Due to the
rare population frequency of suspected disease-causing var-
iants, identifying the balance between speciﬁcity and sensi-
tivity can be achieved only after a signiﬁcant number of
samples have been processed and conﬁrmed. For example,
94% (nZ 166) of false-negatives in the adjusted data set from
our internal database had a variant frequency of 0.1%, or 1
in 1000 samples tested in a high-risk cohort. Moreover, 68%
(nZ 119) were observed in only <1 in 10,000 samples, or
0.01%.Discussion
The ability to simultaneously sequence large numbers of
genes implicated in disease quickly and in a cost-effectiveThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmanner has enabled NGS to rapidly replace Sanger
sequencing as the method of choice in diagnostic-testing
laboratories. As a result, a multitude of gene-sequencing
panels have entered the market, with varying degrees of
sensitivity and speciﬁcity depending on numerous
factors, such as the technologies used for sample enrich-
ment and sequencing, variant-conﬁrmation methods, bio-
informatics pipeline, and variant interpretation. For
hereditary-cancer testing, high sensitivity and speciﬁcity
of an assay are essential as clinicians rely on the data to
make important clinical management decisions such as
costly specialized surveillance, treatment selection, and
preventive surgery. Therefore, missing any cancer-related
mutation or reporting out a false-positive result can have
drastic health care consequences for patients and their
families.
There has been a lot of debate regarding the necessity of
conﬁrming variants detected by NGS with a secondary
technology such as Sanger conﬁrmation. Currently, there
are no speciﬁc guidelines on how diagnostic-testing labo-
ratories should incorporate conﬁrmatory methods. Several
studies have been published recently detailing that Sanger-
sequencing conﬁrmation of NGS variants should not be
required for variants with high coverage and Q scores.
However, these studies have been very small, analyzing
Sanger-conﬁrmation results in only around 100 samples.929
Figure 4 The ability to detect MSH2 mutations is reduced when
the false-positive rate is adjusted to zero. A: As the false-positive rate
of MSH2 is reduced from a baseline value of 2% to 0%, sensitivity is
reduced from 100% to 83.5%. B: Integrative Genomics Viewer
screenshot of a true pathogenic MSH2 c.942þ3A>T mutation located
in a difﬁcult-to-analyze homopolymer stretch of 27 adenine residues,
which is frequently missed when the false-positive rate is adjusted to
zero. Horizontal black bars represent false deletion calls.
Mu et alFurthermore, these studies used variant Q score, which is
ambiguous and highly speciﬁc to their workﬂow, as one of
the main metrics to determine threshold settings.9,10
Here we describe the largest study to date, with 20,000
hereditary-cancer panel samples analyzed by NGS and
nearly 8000 variants Sanger-conﬁrmed. Our data illustrate
that a conservative quality threshold for high-conﬁdence
NGS calls is a minimal read depth coverage of >100 and
a variant allele frequency (or heterozygous ratio) of
>40%. The calls satisfying these thresholds are conﬁdent
to be reported out by NGS without secondary
conﬁrmation. Variant calls not meeting these metrics should
be Sanger-sequenced to ensure the highest possible sensi-
tivity and speciﬁcity of the assay. Importantly, these proper
thresholds can be achieved only after the processing of
thousands of samples because clinically relevant variants are
extremely rare.
To limit Sanger-sequencing variant conﬁrmation
further, one could include manual Integrative Genomics930Viewer (IGV) (Broad Institute) data analysis in the re-
view process. For example, one could lower the hetero-
zygosity ratio threshold to 25%, while keeping the
coverage cutoff the same, and implement IGV review of
variants >25% and <40%. However, we would advise
caution using this approach extensively in a high-volume
diagnostics setting as it requires extensive training and
incorporates subjective judgment by an individual, which
could result in additional errors and test-processing de-
lays. Furthermore, reducing the threshold in regions
known to have pseudogene homology that can confound
sequencing results could be problematic. For example,
SMAD4 has a processed pseudogene found with a fre-
quency of 0.26%, which can confound NGS alignment
and result in erroneous variant calls.23 Considering that
the majority of false-positives occur in difﬁcult-to-
sequence regions, it could be challenging to reliably
discern between false-positives and true calls by visual
inspection of the IGV data.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Necessity of Sanger Sequencing in NGSThe NGS false-positives are primarily due to false
variants in regions difﬁcult to sequence and align such as
A/T- and G/C-rich regions, homopolymer stretches, and
pseudogenes. The adjustment of our bioinformatics
pipeline to reﬂect zero false-positives resulted in missing
2.2% of true clinically relevant mutations, with certain
genes impacted more than others. Our data clearly illus-
trate the dangers of eliminating Sanger conﬁrmation
completely from diagnostic testing. Additionally, NGS
false-positives can be dependent on capture chemistry,
sequencing platform, and analytical pipeline. For
example, false-positives can be more problematic in
primer-based target enrichment than in probe-base
enrichment due to the inability to remove PCR dupli-
cates in the resulting data. In our data set, we did not see a
difference in the false-positive rate when using different
sequence aligners such as the Burrows-Wheeler Aligner
version 0.7.12 (https://sourceforge.net/projects/bio-bwa/
ﬁles) or Bowtie2 (Johns Hopkins University, Baltimore,
MD). We also did not observe any signiﬁcant difference
in the results between the HiSeq2500 and NextSeq500
sequencing platforms, with false-positive rates of 1.3%
and 1.2%, respectively.
It is concerning, the number of publications and
commercially offered clinical diagnostic NGS tests that
claim zero false-positives from the NGS panel data
alone.3e5 Our data illustrate that Sanger conﬁrmation is
needed to keep accuracy high in difﬁcult-to-sequence
regions. In addition, laboratories that keep sensitivity
high but do not Sanger-conﬁrm variants within speciﬁc
parameters will report out false-positives. It is under-
standable why high-volume clinical diagnostics labora-
tories would want to limit Sanger conﬁrmation of NGS
variants as it requires signiﬁcant time and resources. A
slew of new diagnostics companies have entered the
market recently, offering low-priced tests often at the
expense of accuracy by avoiding high-priced steps such
as Sanger-sequencing conﬁrmations and microarrays for
calling deletions and duplications. Likewise, as insurance
companies continue to pressure reimbursement of NGS
tests, laboratories could be forced to limit pricey conﬁr-
mation steps, microarrays, and other side-assays that
impact testing accuracy. It is estimated that Sanger
conﬁrmation costs w$240 per sample and adds an addi-
tional approximately 2 days to test-turnaround times.9
These costs are not trivial for high-volume laboratories.
Based on these estimates, in our 20,000-sample data set
described here, we incurred a cost of $1.9 million to
include Sanger-sequencing conﬁrmation. As a high-
volume diagnostics laboratory, we recommend setting
appropriate quality thresholds for Sanger conﬁrmation
only after processing thousands of samples to accurately
determine problematic regions. To keep the sensitivity
and speciﬁcity of the assay optimal, Sanger conﬁrmation
should be maintained for all variants not meeting these
thresholds.The Journal of Molecular Diagnostics - jmd.amjpathol.orgSupplemental Data
Supplemental material for this article can be found at
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